Related Experiment Video
Updated: Jul 4, 2025
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis
Juguang Zhang1, Weizhong Han2, Jun Guo1
1Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Background:
Non-small cell lung cancers (NSCLC) harboring Human Epidermal Growth Factor Receptor 2 (HER2) mutations represent a distinct subset with unique therapeutic challenges. Although immune checkpoint inhibitors (ICIs) have been transformative in lung cancer treatment, the efficacy of ICIs in HER2-mutated NSCLC remains to be established.
Methods:
We systematically searched for real-world studies investigating the use of ICIs in treating HER2-mutated NSCLC, sourced from the PubMed, Cochrane Library, and Embase databases. Outcomes including objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS) were extracted for further analysis.
Results:
Twelve studies involving 260 patients were enrolled in this meta-analysis. Pooled data revealed an ORR of 0.26 (95% CI 0.17-0.34), a DCR of 0.68 (95% CI 0.55-0.81), and a median PFS (mPFS) of 5.36 months (95% CI 3.50-7.21). Notably, in the subgroup receiving combined immune and chemotherapy, the ORR increased to 0.37 (95% CI 0.26-0.49), the DCR to 0.79 (95% CI 0.70-0.87), and the mPFS to 7.10 months (95% CI 5.21-8.99).
Conclusions:
ICIs demonstrate promising anti-tumor activity and safety in patients with HER2-mutated NSCLC. Furthermore, the combined regimen of ICIs and chemotherapy may provide a significant therapeutic option for this patient population.
Insights
Immune checkpoint inhibitors show promise for HER2-mutated non-small cell lung cancer (NSCLC). Combination therapy with chemotherapy may offer improved outcomes for patients with this NSCLC subtype.
Area of Science:
- Oncology
- Immunotherapy
- Genomics
Background:
- Non-small cell lung cancer (NSCLC) with Human Epidermal Growth Factor Receptor 2 (HER2) mutations presents unique treatment challenges.
- The efficacy of immune checkpoint inhibitors (ICIs) in HER2-mutated NSCLC requires further investigation.
Approach:
- A systematic meta-analysis of real-world studies was conducted.
- Data from PubMed, Cochrane Library, and Embase databases were analyzed.
- Key outcomes included objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS).
Key Points:
- Pooled analysis of 12 studies (260 patients) showed an ORR of 0.26 and median PFS of 5.36 months.
- Combined ICI and chemotherapy demonstrated improved efficacy, with an ORR of 0.37 and median PFS of 7.10 months.
- The safety profile of ICIs in this population was also promising.
Conclusions:
- ICIs exhibit notable anti-tumor activity and a favorable safety profile in HER2-mutated NSCLC.
- Combination therapy with ICIs and chemotherapy represents a potential therapeutic strategy for this patient group.
More Related Videos
11:31Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System
Published on: August 8, 2012
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...